Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prednisone controlled-release - Horizon Pharma/Vectura

Next Previous
Drug Profile

Prednisone controlled-release - Horizon Pharma/Vectura

Alternative Names: Lodotra; Modified-release prednisone - Horizon Pharma/Merck; NP-01; Prednisone MR tablet - Horizon Pharma/Merck; Rayos; Single-pulse delayed-release (SPDR) low-dose prednisone tablet - Horizon

Latest Information Update: 19 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nitec Pharma; SkyePharma PLC
  • Developer Horizon Pharma AG; Merck KGaA; Mundipharma International; Rafa Laboratories
  • Class Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Corticosteroids; Glucocorticoids; Pregnadienediols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Asthma; Chronic obstructive pulmonary disease; Polymyalgia rheumatica; Psoriatic arthritis; Rheumatoid arthritis
  • Discontinued Nocturnal asthma

Most Recent Events

  • 18 Aug 2016 Horizon Pharma receives patent allowance for Prednisone delayed release tablets in USA
  • 15 Mar 2016 Biomarkers information updated
  • 11 Nov 2015 Horizon Pharma plans a phase I trial for Systemic lupus erythematosus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top